We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-3.19%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$522M
AUM Growth
-$148M
Cap. Flow
-$183M
Cap. Flow %
-35.1%
Top 10 Hldgs %
68.85%
Holding
172
New
42
Increased
30
Reduced
27
Closed
64

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$18.7M
2
AZN icon
AstraZeneca
AZN
+$11.5M
3
XWEL icon
XWELL
XWEL
+$3.81M
4
RVPH
REVIVA PHARMA HLDGS INC
RVPH
+$3.63M
5
CVM icon
CEL-SCI Corp
CVM
+$2.66M

Top Sells

Rank Stock Value
1
SRNE
Sorrento Therapeutics, Inc.
SRNE
+$4.87M
2
IMMU
Immunomedics Inc
IMMU
+$4.25M
3
ACAD icon
Acadia Pharmaceuticals
ACAD
+$4.12M
4
SPI
SPI Energy Co., Ltd. Ordinary Shares
SPI
+$3.57M
5
RMTI icon
Rockwell Medical
RMTI
+$3.04M

Sector Composition

Rank Sector Weight
1 Healthcare 17.64%
2 Industrials 0.71%
3 Technology 0.22%
4 Consumer Discretionary 0.14%
5 Consumer Staples 0.1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EFOI icon
101
PUT
Energy Focus
EFOI
$18M
$48K 0.01%
17
– –
INDP icon
102
Indaptus Therapeutics
INDP
$243M
$35K 0.01%
+91
New +$39.7K
NBRV
103
PUT
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$29K 0.01%
5
+1
+25% +$108
BIOL
104
DELISTED
Biolase, Inc.
BIOL
$26K 0.01%
25
-108
-81% -$82.4K
LSTA icon
105
PUT
Lisata Therapeutics
LSTA
$9.93M
$16K ﹤0.01%
7
-102
-94% -$2.42K
ACAD icon
106
Acadia Pharmaceuticals
ACAD
$4.51B
– –
-99,921
Closed -$4.12M
ADTX
107
DELISTED
ADITXT INC
ADTX
– –
0
– -$439K
ALT icon
108
Altimmune
ALT
$568M
– –
-13,800
Closed -$182K
ALT icon
109
PUT
Altimmune
ALT
$568M
– –
-761
Closed -$1M
ATXS
110
CALL
DELISTED
Astria Therapeutics
ATXS
– –
-46
Closed -$171K
ATXS
111
PUT
DELISTED
Astria Therapeutics
ATXS
– –
-149
Closed -$552K
AUPH icon
112
CALL
Aurinia Pharmaceuticals
AUPH
$1.95B
– –
-704
Closed -$1.04M
AZN icon
113
CALL
AstraZeneca
AZN
$269B
– –
-261
Closed -$2.85M
BKYI
114
BIO-key International
BKYI
$4.76M
– –
-69
Closed -$44K
BNTC icon
115
Benitec Biopharma
BNTC
$414M
– –
-698
Closed -$75K
CKPT
116
DELISTED
Checkpoint Therapeutics
CKPT
– –
-93,124
Closed -$2.5M
CLDX icon
117
CALL
Celldex Therapeutics
CLDX
$2.94B
– –
-1,392
Closed -$2.06M
CNVS icon
118
Cineverse
CNVS
$56.9M
– –
-243,797
Closed -$2.75M
COCP icon
119
Cocrystal Pharma
COCP
$12M
– –
-222,274
Closed -$2.48M
CRIS icon
120
CALL
Curis
CRIS
$9.71M
– –
-3
Closed -$132K
CRIS icon
121
Curis
CRIS
$9.71M
– –
-2,949
Closed -$1.38M
CTXR icon
122
Citius Pharmaceuticals
CTXR
$15.6M
– –
-3,548
Closed -$92K
BGMS
123
Bio Green Med Solution Inc
BGMS
$4.86M
– –
-35
Closed -$458K
CYTK icon
124
CALL
Cytokinetics
CYTK
$10.6B
– –
-157
Closed -$340K
HYPD
125
Hyperion DeFi Inc
HYPD
$35.5M
– –
-7,609
Closed -$1.9M
3 4
5
6 7

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
AB
Aozora Bank Tokyo, Japan $43.6M AUM 1.15% 1-Year Est. Return

Sabby Management's Q4 2020 Portfolio in Review

As of Q4 2020, Sabby Management held 172 positions worth $522M, down 22% from $670M the previous quarter. Its ten largest holdings account for 69% of the portfolio.

Sabby Management withdrew a net $183M in Q4 2020, closing 64 positions and reducing 27 holdings. Its most notable exit was Sorrento Therapeutics, Inc., an estimated $4.87M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 18% of assets, up from 12% a quarter earlier, followed by Industrials and Technology.

Against the trend, Sabby Management opened a new position in REVIVA PHARMA HLDGS INC worth $3.13M.

  • Sabby Management's largest Q4 2020 buy was REVIVA PHARMA HLDGS INC: 17,915 shares worth $3.13M.
  • Sabby Management added most to Biogen in Q4 2020, an estimated $18.7M increase.
  • Sabby Management's biggest Q4 2020 reduction was Rockwell Medical, cutting an estimated $3.04M.
  • Sabby Management fully exited Sorrento Therapeutics, Inc. in Q4 2020, selling an estimated $4.87M.
  • Sabby Management's ten largest holdings make up 69% of its $522M portfolio in Q4 2020.
  • Sabby Management opened 42 new positions and closed 64 in Q4 2020.
  • Sabby Management's portfolio value fell 22% quarter-over-quarter to $522M.

Based on Sabby Management's 13F filing for Q4 2020, filed 16 Feb 2021.